{"protocolSection":{"identificationModule":{"nctId":"NCT05086445","orgStudyIdInfo":{"id":"17610"},"secondaryIdInfos":[{"id":"J2A-JE-GZGB","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus","officialTitle":"A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus"},"statusModule":{"statusVerifiedDate":"2026-06-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-11-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-09-05","type":"ACTUAL"},"completionDateStruct":{"date":"2022-09-05","type":"ACTUAL"},"studyFirstSubmitDate":"2021-10-20","studyFirstSubmitQcDate":"2021-10-20","studyFirstPostDateStruct":{"date":"2021-10-21","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-04-30","resultsFirstSubmitQcDate":"2026-06-18","resultsFirstPostDateStruct":{"date":"2026-07-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-06-18","lastUpdatePostDateStruct":{"date":"2026-07-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":62,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"LY3502970 (Part A)","type":"EXPERIMENTAL","description":"Participants received single doses of LY3502970 administered orally.","interventionNames":["Drug: LY3502970"]},{"label":"LY3502970 (Part B)","type":"EXPERIMENTAL","description":"Participants received multiple doses of LY3502970 administered orally.","interventionNames":["Drug: LY3502970"]},{"label":"Placebo (Part A)","type":"PLACEBO_COMPARATOR","description":"Participants received placebo administered orally.","interventionNames":["Drug: Placebo"]},{"label":"Placebo (Part B)","type":"PLACEBO_COMPARATOR","description":"Participants received placebo administered orally.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"LY3502970","description":"Administered orally","armGroupLabels":["LY3502970 (Part A)","LY3502970 (Part B)"]},{"type":"DRUG","name":"Placebo","description":"Administered orally","armGroupLabels":["Placebo (Part A)","Placebo (Part B)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration","description":"A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.","timeFrame":"Baseline Through Follow-Up (Up To Week 15)"}],"secondaryOutcomes":[{"measure":"Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 1","description":"PK: Cmax of LY3502970.","timeFrame":"Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)"},{"measure":"Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1","description":"PK: AUC\\[0-tlast\\] of LY3502970.","timeFrame":"Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)"},{"measure":"Part B: PK: Cmax of LY3502970 on Day 84","description":"PK: Cmax of LY3502970.","timeFrame":"Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)"},{"measure":"Part B: PK: AUC[0-tlast] of LY3502970 on Day 84","description":"PK: AUC\\[0-tlast\\] of LY3502970.","timeFrame":"Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)"},{"measure":"Change From Baseline in Fasting Glucose","description":"Change from Baseline in Fasting Glucose was reported. Least square mean was calculated using the model: Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\\*Timepoint + Participant + Random Error, where participant was fitted as a random effect.","timeFrame":"Baseline through Day 85"},{"measure":"Change From Baseline in Glycated Hemoglobin (HbA1c)","description":"Change from Baseline in HbA1c. Least square mean was calculated using model Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\\*Timepoint + Participant + Random Error, where participant is fitted as a random effect","timeFrame":"Baseline through Day 85"},{"measure":"Change From Baseline in Body Weight","description":"Change from Baseline in Body Weight. Least square mean was calculated using Model: Change from baseline = Baseline + Treatment + Time + Treatment\\*Time + participant + Random Error, where participant was fitted as a random effect","timeFrame":"Baseline through Day 88"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females not of childbearing potential\n* Have type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year\n* Have glycated hemoglobin (HbA1c) value ≥ 7.0% and ≤ 10.0% for participants treated with diet and exercise or HbA1c ≥ 6.5% and ≤ 9.0% for participants who have washed out antidiabetic medications at screening\n* Have type 2 diabetes controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (OAM); either metformin, DPP-4 (dipeptidyl peptidase-4) inhibitor, or SGLT2 (sodium-glucose co-transporter-2) inhibitor within 3 months prior to screening. Participants must withdraw from their OAM treatment for at least 28 days prior to dosing.\n\nExclusion Criteria:\n\n* Have type 1 diabetes mellitus or latent autoimmune diabetes in adults.\n* Have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization\n* Have had an episode of severe hypoglycemia, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery or have a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.\n* Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of \\>500 milligram per deciliter (mg/dL).\n* Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases (alanine aminotransferase \\[ALT\\] and aspartate aminotransferase \\[AST\\]) greater than 3× upper limit of normal (ULN).","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Medical Corporation Heishinkai OPHAC Hospital","city":"Osaka","state":"Osaka","zip":"532-0003","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"P-One Clinic","city":"Hachiōji","state":"Tokyo","zip":"192-0071","country":"Japan","geoPoint":{"lat":35.65583,"lon":139.32389}},{"facility":"Clinical Research Hospital Tokyo","city":"Shinjuku-ku","state":"Tokyo","zip":"162-0053","country":"Japan"},{"facility":"Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic","city":"Toshima City","state":"Tokyo","zip":"171-0014","country":"Japan","geoPoint":{"lat":35.76126,"lon":139.74491}},{"facility":"Yokohama Minoru Clinic","city":"Yokohama","zip":"232-0064","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}}]},"referencesModule":{"seeAlsoLinks":[{"label":"A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus","url":"https://trials.lillytrialguide.com/en-US/trial/19e2wyNokvTUEXgJp8UDry"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.","groups":[{"id":"FG000","title":"Cohort 1a - Placebo","description":"Participants received a single oral dose of Placebo in Part A. Participants who completed Part A continued to Part B where they received oral doses of placebo once daily (QD) for 12 weeks."},{"id":"FG001","title":"Cohort 1a - LY3502970","description":"Participants received a single oral dose of 2 mg LY3502970 in Part A. Participants who completed Part A moved to Part B where they received oral doses of LY3502970 QD as follows: 2 milligrams (mg) (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks)."},{"id":"FG002","title":"Cohort 2a - Placebo","description":"Participants received a single oral dose of Placebo in Part A. Participants who completed Part A continued to Part B where they received oral doses of placebo QD for 12 weeks."},{"id":"FG003","title":"Cohort 2a - LY3502970","description":"Participants received a single oral dose of 3 mg LY3502970 in Part A. Participants who completed Part A moved to Part B where they received oral doses of LY3502970 as follows: 3 mg (2 weeks), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks) and 45 mg (2 weeks)."},{"id":"FG004","title":"Cohort 1b - Placebo QD","description":"Participants received oral doses of placebo QD for 12 weeks."},{"id":"FG005","title":"Cohort 1b - LY3502970 QD","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks)."},{"id":"FG006","title":"Cohort 2b - Placebo QD","description":"Participants received oral doses of placebo QD for 12 weeks."},{"id":"FG007","title":"Cohort 2b - LY3502970 QD","description":"Participants received oral doses of LY3502970 QD for 12 weeks with doses as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks)."},{"id":"FG008","title":"Cohort 3a - Placebo QD","description":"Participants received oral doses of placebo QD for 12 weeks."},{"id":"FG009","title":"Cohort 3a - LY3502970 QD","description":"Participants received oral doses of LY3502970 QD as follows: 3 mg (2 weeks), 6 mg (2 weeks), and 12 mg (8 weeks)."},{"id":"FG010","title":"Cohort 3b - Placebo QD","description":"Participants received oral doses of placebo QD for 12 weeks."},{"id":"FG011","title":"Cohort 3b - LY3502970 QD","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), and 12 mg (8 weeks)."}],"periods":[{"title":"Part A","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Received At Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]}]},{"title":"Part B","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","comment":"This arm is specific to this period only; 10 participants enrolled, including 8 completers from Part A.","numSubjects":"10"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","comment":"This arm is specific to this period only.","numSubjects":"1"},{"groupId":"FG005","comment":"This arm is specific to this period only.","numSubjects":"7"},{"groupId":"FG006","comment":"This arm is specific to this period only.","numSubjects":"2"},{"groupId":"FG007","comment":"This arm is specific to this period only.","numSubjects":"9"},{"groupId":"FG008","comment":"This arm is specific to this period only.","numSubjects":"2"},{"groupId":"FG009","comment":"This arm is specific to this period only.","numSubjects":"7"},{"groupId":"FG010","comment":"This arm is specific to this period only.","numSubjects":"2"},{"groupId":"FG011","comment":"This arm is specific to this period only.","numSubjects":"7"}]},{"type":"Received At Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"7"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"9"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"7"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"8"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All participants who were enrolled in Part A, Part B. A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.","groups":[{"id":"BG000","title":"Placebo - Part A","description":"Participants received a single oral dose of Placebo."},{"id":"BG001","title":"2 mg LY3502970 - Part A","description":"Participants received a single oral dose of 2 mg LY3502970."},{"id":"BG002","title":"3 mg LY3502970 - Part A","description":"Participants received a single oral dose of 3 mg LY3502970."},{"id":"BG003","title":"Placebo QD - Part B","description":"Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A."},{"id":"BG004","title":"3/6/12 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 3 mg (2 weeks), 6 mg (2 weeks), and 12 mg (8 weeks)."},{"id":"BG005","title":"2/3/6/12 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), and 12 mg (8 weeks)."},{"id":"BG006","title":"2/3/6/8/12/24 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 in Part A and completed Part A."},{"id":"BG007","title":"3/6/12/24/36/45 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 3 mg (2 weeks), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks) and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 in Part A and completed Part A."},{"id":"BG008","title":"2/3/6/12/24/36/45 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks)."},{"id":"BG009","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"83"}]}],"measures":[{"title":"Age, Continuous","populationDescription":"A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"title":"Part A","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"23"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"55.5","spread":"1.7"},{"groupId":"BG001","value":"53.1","spread":"11.7"},{"groupId":"BG002","value":"57.6","spread":"5.5"},{"groupId":"BG009","value":"55.3","spread":"8.5"}]}]},{"title":"Part B","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"60"}]}],"categories":[{"measurements":[{"groupId":"BG003","value":"57.7","spread":"5.8"},{"groupId":"BG004","value":"58.0","spread":"6.8"},{"groupId":"BG005","value":"56.3","spread":"8.6"},{"groupId":"BG006","value":"53.4","spread":"10.0"},{"groupId":"BG007","value":"57.6","spread":"5.5"},{"groupId":"BG008","value":"57.7","spread":"7.1"},{"groupId":"BG009","value":"56.1","spread":"8"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Part A","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"23"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"23"}]}]},{"title":"Part B","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"60"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"58"}]}]}]},{"title":"Race (NIH/OMB)","populationDescription":"A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Part A","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"23"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"23"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]}]},{"title":"Part B","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"60"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"60"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}]}]}]},{"title":"Region of Enrollment","populationDescription":"A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Japan","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"23"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"23"}]}]}]},{"title":"Region of Enrollment","populationDescription":"A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Japan","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"60"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"60"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration","description":"A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.","populationDescription":"All participants from Part A and Part B who received at least one dose of study drug. For Part B, as specified in the statistical analysis plan, analyses were performed for the pre-specified treatment groups: placebo, 2(or 3)/3/6/12 mg LY3502970, 2/3/6/8/12/24 mg LY3502970, and 2(or 3)/6/12/24/36/45 mg LY3502970.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Baseline Through Follow-Up (Up To Week 15)","groups":[{"id":"OG000","title":"Placebo - Part A","description":"Participants received a single oral dose of Placebo."},{"id":"OG001","title":"2 mg LY3502970 - Part A","description":"Participants received a single oral dose of 2 mg LY3502970."},{"id":"OG002","title":"3 mg LY3502970 - Part A","description":"Participants received a single oral dose of 3 mg LY3502970."},{"id":"OG003","title":"Placebo QD - Part B","description":"Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A."},{"id":"OG004","title":"2(or 3)/3/6/12 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks)."},{"id":"OG005","title":"2/3/6/8/12/24 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A."},{"id":"OG006","title":"2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"18"}]}],"classes":[{"title":"TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"9"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]}]},{"type":"SECONDARY","title":"Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 1","description":"PK: Cmax of LY3502970.","populationDescription":"Part A participants who received at least one dose of LY3502970 and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)","groups":[{"id":"OG000","title":"2 mg LY3502970 - Part A","description":"Participants received a single oral dose of 2 mg LY3502970."},{"id":"OG001","title":"3 mg LY3502970 - Part A","description":"Participants received a single oral dose of 3 mg LY3502970."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.70","spread":"34"},{"groupId":"OG001","value":"18.1","spread":"38"}]}]}]},{"type":"SECONDARY","title":"Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1","description":"PK: AUC\\[0-tlast\\] of LY3502970.","populationDescription":"Part A participants who received at least one dose of LY3502970 and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram hour per milliliter (ng*h/mL)","timeFrame":"Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)","groups":[{"id":"OG000","title":"2 mg LY3502970 - Part A","description":"Participants received a single oral dose of 2 mg LY3502970."},{"id":"OG001","title":"3 mg LY3502970 - Part A","description":"Participants received a single oral dose of 3 mg LY3502970."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"236","spread":"30"},{"groupId":"OG001","value":"412","spread":"29"}]}]}]},{"type":"SECONDARY","title":"Part B: PK: Cmax of LY3502970 on Day 84","description":"PK: Cmax of LY3502970.","populationDescription":"Part B participants who received at least one dose of study drug and had evaluable PK data. Per protocol, PK analysis was conducted by treatment dose. On Day 84, participants in 12 mg cohort received 12 mg, 24 mg cohort received 24 mg, and 45 mg cohort received 45 mg of LY3502970. Therefore, Cmax of LY3502970 for the respective treatment doses were reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)","groups":[{"id":"OG000","title":"12 mg LY3502970 - Part B","description":"Participants received 12 mg of LY3502970 on Day 84."},{"id":"OG001","title":"24 mg LY3502970 - Part B","description":"Participants received 24 mg of LY3502970 on Day 84."},{"id":"OG002","title":"45 mg LY3502970 - Part B","description":"Participants received 45 mg of LY3502970 on Day 84."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":"37"},{"groupId":"OG001","value":"139","spread":"42"},{"groupId":"OG002","value":"279","spread":"53"}]}]}]},{"type":"SECONDARY","title":"Part B: PK: AUC[0-tlast] of LY3502970 on Day 84","description":"PK: AUC\\[0-tlast\\] of LY3502970.","populationDescription":"Part B participants who received at least one dose of study drug and had evaluable PK data. Per protocol, PK analysis was conducted by treatment dose. On Day 84, participants in 12 mg cohort received 12 mg, 24 mg cohort received 24 mg, and 45 mg cohort received 45 mg of LY3502970. Therefore, AUC\\[0-tlast\\] of LY3502970 for the respective treatment doses were reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram hour per milliliter (ng*h/mL)","timeFrame":"Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)","groups":[{"id":"OG000","title":"12 mg LY3502970 - Part B","description":"Participants received 12 mg of LY3502970 on Day 84."},{"id":"OG001","title":"24 mg LY3502970 - Part B","description":"Participants received 24 mg of LY3502970 on Day 84."},{"id":"OG002","title":"45 mg LY3502970 - Part B","description":"Participants received 45 mg of LY3502970 on Day 84."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5860","spread":"68"},{"groupId":"OG001","value":"7480","spread":"83"},{"groupId":"OG002","value":"11200","spread":"80"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Glucose","description":"Change from Baseline in Fasting Glucose was reported. Least square mean was calculated using the model: Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\\*Timepoint + Participant + Random Error, where participant was fitted as a random effect.","populationDescription":"Part B participants who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data. For Part B, as specified in the statistical analysis plan, analyses were performed for the pre-specified treatment groups: placebo, 2(or 3)/3/6/12 mg LY3502970, 2/3/6/8/12/24 mg LY3502970, and 2(or 3)/6/12/24/36/45 mg LY3502970.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"milligrams per deciliter (mg/dL)","timeFrame":"Baseline through Day 85","groups":[{"id":"OG000","title":"Placebo QD - Part B","description":"Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A."},{"id":"OG001","title":"2(or 3)/3/6/12 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks)."},{"id":"OG002","title":"2/3/6/8/12/24 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A."},{"id":"OG003","title":"2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.40","lowerLimit":"-4.08","upperLimit":"18.89"},{"groupId":"OG001","value":"-64.82","lowerLimit":"-71.18","upperLimit":"-58.46"},{"groupId":"OG002","value":"-61.08","lowerLimit":"-67.12","upperLimit":"-55.03"},{"groupId":"OG003","value":"-65.56","lowerLimit":"-70.91","upperLimit":"-60.22"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-72.22","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-85.35","ciUpperLimit":"-59.09"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-68.48","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-81.46","ciUpperLimit":"-55.50"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-72.97","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-85.64","ciUpperLimit":"-60.30"}]},{"type":"SECONDARY","title":"Change From Baseline in Glycated Hemoglobin (HbA1c)","description":"Change from Baseline in HbA1c. Least square mean was calculated using model Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\\*Timepoint + Participant + Random Error, where participant is fitted as a random effect","populationDescription":"Part B participants who received at least one dose of study drug and had evaluable PD data. For Part B, as specified in the statistical analysis plan, analyses were performed for the pre-specified treatment groups: placebo, 2(or 3)/3/6/12 mg LY3502970, 2/3/6/8/12/24 mg LY3502970, and 2(or 3)/6/12/24/36/45 mg LY3502970.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percentage of HbA1c","timeFrame":"Baseline through Day 85","groups":[{"id":"OG000","title":"Placebo QD - Part B","description":"Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A."},{"id":"OG001","title":"2(or 3)/3/6/12 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks)."},{"id":"OG002","title":"2/3/6/8/12/24 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A."},{"id":"OG003","title":"2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","lowerLimit":"0.20","upperLimit":"1.14"},{"groupId":"OG001","value":"-2.16","lowerLimit":"-2.45","upperLimit":"-1.87"},{"groupId":"OG002","value":"-2.17","lowerLimit":"-2.44","upperLimit":"-1.91"},{"groupId":"OG003","value":"-2.28","lowerLimit":"-2.52","upperLimit":"-2.04"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-2.83","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.38","ciUpperLimit":"-2.28"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-2.84","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.38","ciUpperLimit":"-2.30"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-2.95","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.48","ciUpperLimit":"-2.42"}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Change from Baseline in Body Weight. Least square mean was calculated using Model: Change from baseline = Baseline + Treatment + Time + Treatment\\*Time + participant + Random Error, where participant was fitted as a random effect","populationDescription":"Part B participants who received at least one dose of study drug and had evaluable PD data. For Part B, as specified in the statistical analysis plan, analyses were performed for the pre-specified treatment groups: placebo, 2(or 3)/3/6/12 mg LY3502970, 2/3/6/8/12/24 mg LY3502970, and 2(or 3)/6/12/24/36/45 mg LY3502970.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"kilogram (kg)","timeFrame":"Baseline through Day 88","groups":[{"id":"OG000","title":"Placebo QD - Part B","description":"Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A."},{"id":"OG001","title":"2(or 3)/3/6/12 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks)."},{"id":"OG002","title":"2/3/6/8/12/24 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A."},{"id":"OG003","title":"2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","lowerLimit":"-2.3","upperLimit":"1.3"},{"groupId":"OG001","value":"-3.4","lowerLimit":"-5.0","upperLimit":"-1.7"},{"groupId":"OG002","value":"-6.9","lowerLimit":"-8.4","upperLimit":"-5.4"},{"groupId":"OG003","value":"-4.9","lowerLimit":"-6.3","upperLimit":"-3.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-2.9","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.3","ciUpperLimit":"-0.4"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-6.4","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.7","ciUpperLimit":"-4.0"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"LS Mean Difference","paramValue":"-4.3","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.6","ciUpperLimit":"-2.1"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline Through Follow-Up (Up To Week 15)","description":"All participants from Part A and Part B who received at least one dose of study drug. For Part B, as specified in the statistical analysis plan, analyses were performed for the pre-specified treatment groups: placebo, 2(or 3)/3/6/12 mg LY3502970, 2/3/6/8/12/24 mg LY3502970, and 2(or 3)/6/12/24/36/45 mg LY3502970.","eventGroups":[{"id":"EG000","title":"Placebo - Part A","description":"Participants received a single oral dose of Placebo.","deathsNumAffected":0,"deathsNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"otherNumAffected":2,"otherNumAtRisk":4},{"id":"EG001","title":"2 mg LY3502970 - Part A","description":"Participants received a single oral dose of 2 mg LY3502970.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":5,"otherNumAtRisk":10},{"id":"EG002","title":"3 mg LY3502970 - Part A","description":"Participants received a single oral dose of 3 mg LY3502970.","deathsNumAffected":0,"deathsNumAtRisk":9,"seriousNumAffected":0,"seriousNumAtRisk":9,"otherNumAffected":6,"otherNumAtRisk":9},{"id":"EG003","title":"Placebo QD - Part B","description":"Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"otherNumAffected":5,"otherNumAtRisk":11},{"id":"EG004","title":"2(or 3)/3/6/12 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks).","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":11,"otherNumAtRisk":14},{"id":"EG005","title":"2/3/6/8/12/24 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A.","deathsNumAffected":0,"deathsNumAtRisk":17,"seriousNumAffected":0,"seriousNumAtRisk":17,"otherNumAffected":13,"otherNumAtRisk":17},{"id":"EG006","title":"2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B","description":"Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":9,"otherNumAtRisk":18}],"otherEvents":[{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":2,"numAffected":1,"numAtRisk":18}]},{"term":"Diabetic retinopathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Vitreous haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Anal fissure","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG005","numEvents":4,"numAffected":3,"numAtRisk":17},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":18}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG004","numEvents":10,"numAffected":9,"numAtRisk":14},{"groupId":"EG005","numEvents":10,"numAffected":4,"numAtRisk":17},{"groupId":"EG006","numEvents":7,"numAffected":6,"numAtRisk":18}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":10},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG005","numEvents":4,"numAffected":2,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Application site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Medical device site dermatitis","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Asymptomatic covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Eyelid injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Lip injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Blood triglycerides increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Heart rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":14},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":18}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Head discomfort","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"Hyperaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":18}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Dermal cyst","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Eczema asteatotic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":18}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":18}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-10-19","uploadDate":"2024-06-19T23:51","filename":"Prot_000.pdf","size":6168087},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-01-31","uploadDate":"2024-06-19T23:52","filename":"SAP_001.pdf","size":1205148}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000729680","term":"orforglipron"}]}},"hasResults":true}